Canlyniadau Chwilio - Anthony C. Faber

Mireinio'r Canlyniadau
  1. 1
    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics gan Aaron N. Hata, Jeffrey A. Engelman, Anthony C. Faber

    Cyhoeddwyd 2015
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Classification of gastrointestinal stromal tumor syndromes

    Classification of gastrointestinal stromal tumor syndromes gan Priya Gopie, Lin Mei, Anthony C. Faber, Steven R. Grossman, Steven C. Smith, Sosipatros A. Boikos

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Gastrointestinal Stromal Tumors: The GIST of Precision Medicine

    Gastrointestinal Stromal Tumors: The GIST of Precision Medicine gan Lin Mei, Steven C. Smith, Anthony C. Faber, Jonathan C. Trent, Steven R. Grossman, Constantine A. Stratakis, Sosipatros A. Boikos

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i>-Mutant Lung Cancer

    Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i>-Mutant Lung Cancer gan Hidenori Kitai, Hiromichi Ebi, Shuta Tomida, Konstantinos V. Floros, Hiroshi Kotani, Yuta Adachi, Satoshi Oizumi, Masaharu Nishimura, Anthony C. Faber, Seiji Yano

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

    Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins gan Marta Guix, Anthony C. Faber, Shizhen Emily Wang, Maria G. Olivares, Youngchul Song, Sherman Qu, Cammie Rinehart, Brenda Seidel, Douglas Yee, Carlos L. Arteaga, Jeffrey A. Engelman

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways

    Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways gan S. Michael Rothenberg, Kyle Concannon, Sarah Cullen, Gaylor Boulay, Alexa B. Turke, Anthony C. Faber, Elizabeth L. Lockerman, Miguel N. Rivera, Jeffrey A. Engelman, Shyamala Maheswaran, Daniel A. Haber

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

    PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 gan Hiromichi Ebi, Carlotta Costa, Anthony C. Faber, Madhuri Nishtala, Hiroshi Kotani, Dejan Juric, Patricia Della Pelle, Youngchul Song, Seiji Yano, Mari Mino‐Kenudson, Cyril H. Benes, Jeffrey A. Engelman

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X<sub>L</sub>–BAX interaction

    Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X<sub>L</sub>–BAX interaction gan Tareq Saleh, Valerie J. Carpenter, Liliya Tyutyunyk‐Massey, Graeme Murray, Joel D. Leverson, Andrew J. Souers, Moureq R. Alotaibi, Anthony C. Faber, Jason Reed, Hisashi Harada, David A. Gewirtz

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

    Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition gan Anthony C. Faber, Danan Li, Young-Chul Song, Mei‐Chih Liang, Beow Y. Yeap, Roderick T. Bronson, Eugene Lifshits, Chen Zhao, Sauveur-Michel Maira, Carlos Garcı́a-Echeverrı́a, Kwok‐Kin Wong, Jeffrey A. Engelman

    Cyhoeddwyd 2009
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

    Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers gan Aaron N. Hata, Alan T. Yeo, Anthony C. Faber, Eugene Lifshits, Zhao Chen, Katherine A. Cheng, Zandra E. Walton, Kristopher A. Sarosiek, Anthony Letai, Rebecca S. Heist, Mari Mino‐Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation

    An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation gan Birgit Schoeberl, Anthony C. Faber, Danan Li, Mei‐Chih Liang, Katherine Crosby, Matthew Onsum, Olga Burenkova, Emily Pace, Zandra E. Walton, Lin Nie, Aaron Fulgham, Youngchul Song, Ulrik B. Nielsen, Jeffrey A. Engelman, Kwok‐Kin Wong

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

    Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer gan Carlotta Costa, Hiromichi Ebi, Miriam Martini, Sean A. Beausoleil, Anthony C. Faber, Charles T. Jakubik, Alan Huang, Youzhen Wang, Madhuri Nishtala, Ben A. Hall, Klarisa Rikova, Jean J. Zhao, Emilio Hirsch, Cyril H. Benes, Jeffrey A. Engelman

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of <i>BRAFV600E</i> Colorectal Cancer

    Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of <i>BRAFV600E</i> Colorectal Cancer gan Erin M. Coffee, Anthony C. Faber, Jatin Roper, Mark J. Sinnamon, Gautam Goel, Lily Keung, Wei Vivian Wang, Loredana Vecchione, Veerle de Vriendt, Barbara Weinstein, Roderick T. Bronson, Sabine Tejpar, Ramnik J. Xavier, Jeffrey A. Engelman, Eric S. Martin, Kenneth E. Hung

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer

    Therapeutically targeting tumor microenvironment–mediated drug resistance in estrogen receptor–positive breast cancer gan Kevin Shee, Wei Yang, John W. Hinds, Riley A. Hampsch, Frederick S. Varn, Nicole A. Traphagen, Kishan Patel, Chao Cheng, Nicole P. Jenkins, Arminja N. Kettenbach, Eugene Demidenko, Philip Owens, Anthony C. Faber, Todd R. Golub, Ravid Straussman, Todd W. Miller

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma

    Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma gan Timothy L. Lochmann, Krista M. Powell, Jungoh Ham, Konstantinos V. Floros, Daniel A.R. Heisey, Richard Kurupi, Marissa L. Calbert, Maninderjit S. Ghotra, Patricia Greninger, Mikhail G. Dozmorov, Madhu Gowda, Andrew J. Souers, C. Patrick Reynolds, Cyril H. Benes, Anthony C. Faber

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma

    TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF-</i> Mutant Melanoma gan Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John R. Walsh, Mari Mino‐Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    <i>MYCN</i>-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis

    <i>MYCN</i>-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis gan Konstantinos V. Floros, Jinyang Cai, Sheeba Jacob, Richard Kurupi, Carter K. Fairchild, Mayuri Shende, Colin M. Coon, Krista M. Powell, B. Ross Belvin, Bin Hu, Madhavi Puchalapalli, Sivapriya Ramamoorthy, Kimberly Swift, Janina P. Lewis, Mikhail G. Dozmorov, John Glod, Jennifer E. Koblinski, Sosipatros A. Boikos, Anthony C. Faber

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression

    Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression gan Timothy L. Lochmann, Konstantinos V. Floros, Mitra Naseri, Krista M. Powell, Wade Cook, Ryan J. March, Giovanna T. Stein, Patricia Greninger, Yuki Kato Maves, Laura R. Saunders, Scott J. Dylla, Carlotta Costa, Sosipatros A. Boikos, Joel D. Leverson, Andrew J. Souers, Geoffrey W. Krystal, Hisashi Harada, Cyril H. Benes, Anthony C. Faber

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

    Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models gan Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Kenneth E. Hung, Toshi Shioda, Dora Dias‐Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino‐Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1

    mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 gan Anthony C. Faber, Erin M. Coffee, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J. Edelman, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: